Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells

Cancer Research

Volumn 57, Issue 12, 1997, Pages 2508-2515

  Cherney, Barry W ^a,c   Bhatia, Kishor G ^b   Sgadari, Cecilia ^a   Gutierrez, Marina I ^b   Mostowski, Howard ^a   Pike, Sandra E ^a   Gupta, Ghanshyam ^a   Magrath, Ian T ^b   Tosato, Giovanna ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANIMAL CELL; ARTICLE; BURKITT LYMPHOMA; DNA BINDING; DNA DAMAGE; GENE ACTIVATION; GENE REPRESSION; GENE TRANSLOCATION; LYMPHOMA CELL; MARKER GENE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TUMOR SUPPRESSOR GENE;

ANIMALS; BIOPSY; BURKITT LYMPHOMA; CELL CYCLE; FEMALE; GENES, P53; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NOCODAZOLE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030983466     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Mugrath, I. T. Pathogenesis of Burkitt's lymphoma. In: Vande Woude, G. (ed.), Advances in Cancer Research, pp. 136-170. San Diego, CA: Academic Press, 1990.
2. Hausen, H. Z., Sehulte-Holthausen, H., Klein, G., Henle, W., Henle, G., Clifford, P., and Santesson, L. HBV DNA in biopsies of Burkitt tumors and anaplastic carcinomas of the nasopharynx. Nature (Lond.), 228: 1056-1058, 1970.
3. Tosato, G., Taga, K., Angiolillo, A., and Sgadari, C. Epstein-Barr virus as an agent of haematological disease. Bailliere's Clin. Haematol., 8: 165-199, 1995.
4. Dalla-Favera, R., Erilkson, J., Patterson, D., Gallo, R. C., and Croce, C. M. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Proc. Natl. Acad. Sci. USA, 79: 7824-7827, 1982.
5. Hotchin, N., Allday, M. J., and Crawford, D. H. Deregulated c-myc expression in Epstein-Barr virus-immortalized B-cells induces altered growth properties and surface phenotype but not tumorigenicity. Int. J. Cancer, 45: 566-571, 1990.
6. Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., and Brinster, R. L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (Lond.), 318: 533-538, 1985.
7. Henderson, S., Rowe, M., Gregory, C., Croom-Carter, D., Wang, F., Kieff, E., and Rickinson, A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 65: 1-20, 1991.
8. Bhatia, K., Huppi, K., Spangler, G., Siwarski, D., Iyer, R., and Magrath, I. T. Point mutations in the c-myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat. Genet., 5: 56-61, 1993.
9. Farrell, P. J., Alen, G. J., Shanahan, F., Vousden, D. H., and Crook, T. p53 is frequently mutated in Burkitt's lymphoma. EMBO J., 10: 2879-2887, 1991.
10. Gaidano, F., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M., and Dalla-Favera, R. p53 mutations in human lymphoid malignancies: association with Burkitt's lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 88: 5413-5417, 1991.
11. Bhatia, K. G., Gutierrez, M. I., Huppi, K,. Siwarski, D., and Magrath, I. T. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res., 52: 4273-4276, 1992.
12. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F. J., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., and Tainsky, M. A. Germline p53 mutations , in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC), 250: 1233-1238, 1990.
13. Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S. and Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature (Lond.), 356: 211-215, 1992.
14. Finlay, C. A., Hinds, P. W., and Levine, A. J. The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57: 1083-1093, 1989.
15. Farmer, G. E., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., and Prives, C. Wild-type p53 activates transcription in vitro. Nature (Lond.), 358: 83-86, 1992.
16. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. Wafl, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
17. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell, 71: 587-597, 1992.
18. Zban, Q., Fan, S., Bae, I., Guillouf, C., Liebermann, D. A., O'Connor, P. M., and Furnace, A. J. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene, 9: 3743-3751, 1994.
19. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Washington DC), 265: 1582-1584, 1994.
20. Harper, J. W., Adams, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
21. Hunter, T., and Pines, J. Cyclins and cancer II: cyclin D and cdk inhibitors come of age. Cell, 79: 573-582, 1994.
22. Mack, D. H., Vartikar, J., Pipas, J. M., and Laimins, L. A. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature (Lond.), 363: 281-284, 1993.
23. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4: 42-45, 1993.
24. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776-4780, 1993.
25. Pike, S. E., Markey, D. P., Ijames, C., Jones, K. D., and Tosato, G. The role of lactic acid in autocrine B-cell growth stimulation. Proc. Natl. Acad. Sci. USA, 88: 11081-11085, 1991.
26. Bhatia, K., Fan, S., Spangler, G., Weintraub, M., O'Connor, P. M., Judde, J. G., and Magrath, I. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res., 55: 1431-1435, 1995.
27. Baker, S. J., Markowilz, S., Fearon, E. R., Wilson, J. K., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
28. Kessis, T. D., Slebos, R. J., Nelson, W. G., and Kastan, M. B. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA, 90: 3988-3992, 1993.
29. Shiramizu, B., Barriga, F., Neequaye, J., Jafri, A., Dalla-Favera, R., Neri, A., Gutierrez, M., Levine, P., and Magrath, I. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood, 77: 1516-1526, 1991.
30. Kastan, M. B., Onyekwere, O., Sidransky, D., and Vogelstein, B. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
31. cip/waf1 proteins following γ-irradiation of human lymphoma cells. Cancer Res., 55: 2387-2393, 1995.
32. Sheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
33. Medcalf, E. A., and Milner, J. Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation. Oncogene, 8: 2847-2851, 1993.
34. Lowe, S. W., Jacks, T., Housman, D. E., and Ruley, H. E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. USA, 91: 2026-2030, 1994.
35. Pietsch, T., Scharmann, T., Fonatsch, C., Schmidt, D., Ockler, R., Freiholf, D., Albrecht, S., Wiestler, O. D., Zeltzer, P., and Riehm, H. Characterization of five new cell lines derived from human primitive neuroectodermal tumors of the central nervous system. Cancer Res., 54: 3278-3287, 1994.
36. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis by c-myc protein. Cell, 69: 119-128, 1992.
37. Askew, D. S., Ihle, J. N., and Cleveland, J. L. Activation of apoplosis associated with enforced myc expression in myeloid progenitor cells is dominant to the suppression of apoptosis by interleukin-3 or erythropoietin. Blood, 82: 2079-2087, 1993.
38. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.), 379: 88-91, 1996.
39. Fujita, M., and Shiku, H. Differences in sensitivity to induction of apoptosis among rat fibroblast cells transformed by HTLV-1 or cellular nuclear oncogenes. Oncogene, 11: 15-20, 1995.
40. Lotem, J., and Sachs, L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth & Differ., 4: 41-47, 1993.
41. Hermeking, H., and Eick, D. Mediation of c-myc-induced apoptosis by p53. Nature (Lond.), 265: 2091-2093, 1994.
42. Gottlieb, E., Haffner, R., von Ruden, T., Wagner, E. F., and Oren, M. Down-regulation of wild-type p53 activity interferes with apoplosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J., 13: 1368-1374, 1994.
43. Wang, L., Rayanade, R. J., Garcia, D., Patel, K., Pan, H., and Sehgal, P. B. Modulation of interleukin-6-induced plasma protein secretion in hepatoma cells by p53 species. J. Biol. Chem., 270: 23159-23165, 1995.
44. Lotem, J., and Sachs, L. A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decreased in leukemogenicity. Proc. Natl. Acad. Sci. USA, 92: 9672-9676, 1995.